This is a spontaneous report from a contactable physician based on the information received by Pfizer from Biogen 
Idec (Case Ref# 2014BI111882). 
A 50-year-old female patient was on natalizumab (TYSABRI) (300mg, IV. QM) for multiple sclerosis from an 
unknown date to Aug2014 and was hospitalized from an unknown date for PML (progressive multifocal 
leucoencephalopathy) suspicion (onset date: (b) (6) ). No prior immunosuppressive therapy before starting 
Tysabri was reported.
As of Aug2014 when the patient had decided to stop TYSABRI therapy, the patient had received a total of 48 
infusions. The patient switched to methylprednisolone sodium succinate (SOLU-MEDROL) for multiple sclerosis 
and received 1 course in Sep2014. JCV serology was positive on an unknown date and a brain MRI performed on 
(b) (6)  was suggestive of PML suspicion therefore the patient was hospitalized. According to the patient, she 
had presented with visual and speech disorder which started a few days earlier. A lumbar puncture was planned on 
(b) (6)  and CSF samples would be sent for JCV DNA testing. The action taken with natalizumab was 
permanently withdrawn in Aug2014, and with methylprednisolone sodium succinate was unknown. The outcome of 
the event PML suspicion was unknown. The causality for the event of PML suspicion was unknown. No further 
information was provided.
Follow-up (14Jan2015): Follow-up attempts completed. No further information expected.
Follow Up (21Jan2015): This is a follow up spontaneous report based on the information received by Pfizer from 
Biogen Idec (Case Ref# 2014BI111882). New information included: Patient's initials provided. 
No follow up attempts completed. No further information expected.